CONMED (NYSE:CNMD) Releases Quarterly Earnings Results, Beats Estimates By $0.04 EPS

CONMED (NYSE:CNMD) issued its quarterly earnings data on Wednesday. The company reported $1.04 EPS for the quarter, topping analysts’ consensus estimates of $1.00 by $0.04, FiscalAI reports. CONMED had a return on equity of 14.31% and a net margin of 4.12%. The firm had revenue of $335.56 million during the quarter, compared to the consensus estimate of $336.28 million. During the same period in the prior year, the business earned $1.08 EPS. The firm’s revenue was down .7% on a year-over-year basis.

Here are the key takeaways from CONMED’s conference call:

• Q3 performance exceeded expectations: Organic constant-currency revenue grew 6.7%, while adjusted EPS of $1.04 surpassed the high end of management’s prior outlook.
• Growth was broad-based across the portfolio, led by AirSeal, direct Buffalo Filter smoke evacuation, and BioBrace. General surgery grew 6.4% and orthopedics grew 7.2% organically, with particularly strong international performance.
• Management highlighted significant longer-term growth opportunities, including AirSeal’s low penetration in laparoscopic procedures, expanding smoke-evacuation legislation across 23 states, and new BioBrace regulatory clearance in Brazil.
• Management narrowed 2026 organic constant-currency revenue growth guidance to 5%–5.5% from 5%–6%, citing a more measured sequential improvement outlook and the expectation that favorable international distributor-order timing in Q3 will not repeat in Q4.
• Higher borrowing costs following the debt refinancing increased Q3 interest expense to $10.5 million from $6.3 million, while U.S. orthopedic sales declined 1.7% and OEM smoke-evacuation demand remained variable.

CONMED Stock Performance

Shares of CNMD traded down $0.51 during trading hours on Thursday, hitting $45.25. The company had a trading volume of 124,065 shares, compared to its average volume of 504,745. The company has a quick ratio of 0.69, a current ratio of 1.48 and a debt-to-equity ratio of 0.63. The business has a fifty day moving average of $47.32 and a 200-day moving average of $41.43. CONMED has a 12 month low of $31.44 and a 12 month high of $53.66. The firm has a market cap of $1.36 billion, a price-to-earnings ratio of 24.54, a PEG ratio of 2.25 and a beta of 0.94.

Wall Street Analysts Forecast Growth

A number of research firms recently commented on CNMD. Zacks Research raised shares of CONMED from a “strong sell” rating to a “hold” rating in a research note on Tuesday, August 11th. BMO Capital Markets started coverage on CONMED in a research report on Wednesday, July 8th. They issued a “market perform” rating and a $36.00 price target for the company. Weiss Ratings raised shares of CONMED from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Wednesday, October 21st. Wall Street Zen upgraded shares of CONMED from a “hold” rating to a “buy” rating in a report on Monday, July 20th. Finally, Needham & Company LLC reissued a “hold” rating on shares of CONMED in a research note on Monday, July 13th. Seven analysts have rated the stock with a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, CONMED presently has an average rating of “Reduce” and an average price target of $42.00.

Key CONMED News

Here are the key news stories impacting CONMED this week:

• Positive Sentiment: Wells Fargo raised its price target on CONMED from $46 to $49 while maintaining an “equal weight” rating. The higher target suggests modest potential upside and provides some support for the stock’s valuation. Wells Fargo CONMED price-target update
• Positive Sentiment: Third-quarter adjusted EPS was $1.04, beating the $1.00 consensus estimate. The earnings beat indicates better-than-expected profitability for the quarter, and reports characterized quarterly profit as higher. CONMED Q3 earnings beat
• Neutral Sentiment: Management updated its full-year 2026 guidance. The guidance revision will be important for investors assessing whether the earnings beat reflects sustainable growth, although the provided reports do not include the updated figures. CONMED updates 2026 guidance
• Negative Sentiment: Revenue of $335.56 million was slightly below the $336.28 million analyst consensus and declined 0.7% from the prior year. EPS also fell from $1.08 to $1.04 year over year, signaling limited near-term growth despite the quarterly earnings beat. CONMED third-quarter earnings results

CONMED Company Profile

CONMED Corporation is a medical technology company that develops, manufactures, and sells surgical devices and related equipment. Its products are used by hospitals, ambulatory surgery centers, and other healthcare providers in orthopedic and general surgery procedures.

The company’s orthopedic portfolio includes arthroscopy systems, powered surgical instruments, sports medicine products, tissue ablation systems, implants, and related accessories. Its general surgery offerings include electrosurgical equipment, insufflation systems, smoke evacuation products, surgical visualization technologies, and devices used in minimally invasive procedures.

Founded in 1970, CONMED serves healthcare customers through direct sales and distribution channels in the United States and international markets.